IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy
Wang, Lei1,2,4; Fu, Jia-ning2,4; Wang, Jing-yu2,4; Jin, Cun-jing2,4; Ren, Xiao-yuan2,4; Tan, Qiang1,2,4; Li, Jing2,4; Yin, Han-wei3; Xiong, Kun3; Wang, Tian-yu3; Liu, Xin-min1; Zeng, Hui-hui2,4
关键词ethaselen NF-kappa B non-small cell lung cancer radiosensitizer thioredoxin reductase inhibitor
刊名ANTI-CANCER DRUGS
2011-09-01
DOI10.1097/CAD.0b013e32834618bc
22期:8页:732-740
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Pharmacology & Pharmacy
资助者Natural Science Foundation of China ; Natural Science Foundation of China
研究领域[WOS]Oncology ; Pharmacology & Pharmacy
关键词[WOS]IONIZING-RADIATION ; KAPPA-B ; APOPTOSIS ; LINES ; CARBOPLATIN ; THERAPY ; GROWTH ; EXPRESSION ; MECHANISM
英文摘要

It has been proposed that thioredoxin reductase (TR) is a mediator that allows non-small cell lung cancer (NSCLC) to develop resistance to irradiation; however, little is known regarding the detailed mechanisms of action. Thus, ethaselen {1, 2-[bis (1,2-benzisoselenazolone-3 (2H)-ketone)] ethane, BBSKE}, a novel organoselenium TR inhibitor, is currently being investigated in a phase I clinical trial in China. However, its radiosensitizing effect remains unexplored. In this study, we found that the activity of TR increased dramatically in both A549 and H1299 cells after radiation, and moreover, could be inhibited by pretreatment with BBSKE (5 mu mol/l). As a TR inhibitor, BBSKE enhanced the efficacy of radiation therapy both in vivo and in vitro without observable toxicity. BBSKE was found to suppress irradiation-induced NF-kappa B activation dramatically when using A549 cells stably transfected with NF-kappa B luciferase reporter. These results show the critical role of TR in the radioresistance of NSCLC and suggest that BBSKE is a potentially promising agent for the treatment of patients with NSCLC clinically. Anti-Cancer Drugs 22:732-740 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.

语种英语
所属项目编号30472036
资助者Natural Science Foundation of China ; Natural Science Foundation of China
WOS记录号WOS:000293212800004
引用统计
被引频次:16[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62847
专题北京大学第一临床医学院
作者单位1.Peking Univ, Hosp 1, Beijing 100034, Peoples R China
2.Peking Univ, Coll Life Sci, Beijing 100034, Peoples R China
3.Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing, Peoples R China
4.Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Beijing 100034, Peoples R China
推荐引用方式
GB/T 7714
Wang, Lei,Fu, Jia-ning,Wang, Jing-yu,et al. Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy[J]. ANTI-CANCER DRUGS,2011,22(8):732-740.
APA Wang, Lei.,Fu, Jia-ning.,Wang, Jing-yu.,Jin, Cun-jing.,Ren, Xiao-yuan.,...&Zeng, Hui-hui.(2011).Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy.ANTI-CANCER DRUGS,22(8),732-740.
MLA Wang, Lei,et al."Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy".ANTI-CANCER DRUGS 22.8(2011):732-740.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Lei]的文章
[Fu, Jia-ning]的文章
[Wang, Jing-yu]的文章
百度学术
百度学术中相似的文章
[Wang, Lei]的文章
[Fu, Jia-ning]的文章
[Wang, Jing-yu]的文章
必应学术
必应学术中相似的文章
[Wang, Lei]的文章
[Fu, Jia-ning]的文章
[Wang, Jing-yu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。